Bergamo Acquisition Corp. (BGMO)

[Greengo]

Try reading VSTA filings !!

Autilion AG is a Bergamo Acquisition Corp Subsidiary in Europe.


http://www.otcmarkets.com/stock/VSTA/filings


On April 8, 2013, VistaGen Therapeutics, Inc. (the “ Company ”) and On April 8, 2013, VistaGen Therapeutics, Inc. (the “ Company ”) and Autilion AG (the “ Purchaser ”) entered into a Securities
Purchase Agreement pursuant to which the Company has agreed to sell, and the Purchaser has agreed to purchase, 72.0 million shares of the
Company’s Common Stock, for $0.50 per share, on or before April 30, 2013 (the “ Financing ”). The Securities Purchase Agreement contains
standard representations and warranties and provides that closing is subject to usual and customary closing conditions. The Securities Purchase
Agreement also provides for the election of one designee of the Purchaser to the Company’s Board of Directors. (the “ Purchaser ”) entered into a Securities
Purchase Agreement pursuant to which the Company has agreed to sell, and the Purchaser has agreed to purchase, 72.0 million shares of the
Company’s Common Stock, for $0.50 per share, on or before April 30, 2013 (the “ Financing ”). The Securities Purchase Agreement contains
standard representations and warranties and provides that closing is subject to usual and customary closing conditions. The Securities Purchase
Agreement also provides for the election of one designee of the Purchaser to the Company’s Board of Directors.


On April 30, 2013, VistaGen Therapeutics, Inc. (the “ Company ”) and Bergamo Acquisition Corp. PTE LTD (“ Bergamo ”) entered
into an amendment (the “ Amendment ”) to the Securities Purchase Agreement (the “ Agreement ”), dated April 8, 2013, and assigned to
Bergamo pursuant to the terms of an Assignment and Assumption Agreement, dated April 12, 2013. The Amendment amends the scheduled
investment dates, so that the first closing shall occur on or before May 15, 2013 and the final closing shall occur on or before September 30,
2013, as more particularly set forth below:
The foregoing description of the Amendment does not purport to be complete, and is qualified in its entirety by reference to the text of
the Amendment, which is attached hereto as Exhibit 10.1 and incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
Investment Date Total Amount of Investment Total No. of Shares
On or before May 15, 2013 $1,000,000 2,000,000
On or before May 31, 2013 $2,000,000 4,000,000
On or before June 30, 2013 $8,250,000 16,500,000
On or before July 30, 2013 $8,250,000 16,500,000
On or before August 31, 2013 $8,250,000 16,500,000
On or before September 30, 2013 $8,250,000 16,500,000